288 related articles for article (PubMed ID: 33936956)
1. Early SUV
Zhang J; Shi X; Xiao Y; Ma C; Cao G; Liu Y; Li Y
Quant Imaging Med Surg; 2021 May; 11(5):1680-1691. PubMed ID: 33936956
[TBL] [Abstract][Full Text] [Related]
2. Differential diagnosis between (18)F-FDG-avid metastatic lymph nodes in non-small cell lung cancer and benign nodes on dual-time point PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Sugi K; Okabe K; Matsumoto T; Ueda K; Tanaka N; Matsunaga N
Ann Nucl Med; 2009 Aug; 23(6):523-31. PubMed ID: 19444550
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
[TBL] [Abstract][Full Text] [Related]
5. Implications of standardized uptake value measurements of the primary lesions in proven cases of breast carcinoma with different degree of disease burden at diagnosis: does 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography predict tumor biology?
Basu S; Mavi A; Cermik T; Houseni M; Alavi A
Mol Imaging Biol; 2008; 10(1):62-6. PubMed ID: 18000713
[TBL] [Abstract][Full Text] [Related]
6. Dual-phase F-18 FDG PET-CT in staging and lymphoscintigraphy for detection of sentinel lymph nodes in oral cavity cancers.
Sürücü E; Polack BD; Demir Y; Durmuşoğlu M; Ekmekçi S; Sarıoğlu S; Çelik AO; Ada E; İkiz AÖ
Clin Imaging; 2015; 39(5):781-6. PubMed ID: 25721710
[TBL] [Abstract][Full Text] [Related]
7. Improved detection of metastatic lymph nodes in oesophageal squamous cell carcinoma by combined interpretation of fluorine-18-fluorodeoxyglucose positron-emission tomography/computed tomography.
Lee JY; Kim YH; Park YJ; Park SB; Chung HW; Zo JI; Shim YM; Lee KS; Choi JY
Cancer Imaging; 2019 Jun; 19(1):40. PubMed ID: 31227017
[TBL] [Abstract][Full Text] [Related]
8. Differentiation of FDG-avid loco-regional recurrent and compromised benign lesions after surgery for breast cancer with dual-time point F-18-fluorodeoxy-glucose PET/CT scan.
Suga K; Kawakami Y; Hiyama A; Matsunaga N
Ann Nucl Med; 2009 Jun; 23(4):399-407. PubMed ID: 19452249
[TBL] [Abstract][Full Text] [Related]
9. Preliminary clinical assessment of dynamic
Shinya T; Otomi Y; Kubo M; Kinoshita M; Takechi K; Uyama N; Yamanaka M; Terazawa K; Toba H; Bando Y; Otsuka H; Harada M
Ann Nucl Med; 2019 Jun; 33(6):414-423. PubMed ID: 30911883
[TBL] [Abstract][Full Text] [Related]
10. The Value of Dual Time Point
Zhou X; Lu Z; Zhang R; Zhang R; Huang G; Shi K; Chen H; Liu J
Acad Radiol; 2024 Mar; ():. PubMed ID: 38431484
[TBL] [Abstract][Full Text] [Related]
11. The Predictive Value of Early Changes in
He M; Liu C; Shi Q; Sun Y; Zhang Y; Xu X; Yuan H; Zhang Y; Liu Y; Liu G; Di G; Yang Z; Wang Z; Shao Z
Oncologist; 2020 Nov; 25(11):927-936. PubMed ID: 32272493
[TBL] [Abstract][Full Text] [Related]
12. Value of [
Deleu AL; Laenen A; Decaluwé H; Weynand B; Dooms C; De Wever W; Jentjens S; Goffin K; Vansteenkiste J; Van Laere K; De Leyn P; Nackaerts K; Deroose CM
EJNMMI Res; 2022 May; 12(1):28. PubMed ID: 35524900
[TBL] [Abstract][Full Text] [Related]
13. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine-18)-fluoro-2-deoxy-D-glucose.
Avril N; Dose J; Jänicke F; Ziegler S; Römer W; Weber W; Herz M; Nathrath W; Graeff H; Schwaiger M
J Natl Cancer Inst; 1996 Sep; 88(17):1204-9. PubMed ID: 8780629
[TBL] [Abstract][Full Text] [Related]
14. Assessing
Sarikaya I; Sarikaya A
J Nucl Med Technol; 2019 Jun; 47(2):149-153. PubMed ID: 30413593
[No Abstract] [Full Text] [Related]
15. [Qualitative and quantitative PET/MRI in the evaluation of axillary lymph node metastasis in patients with breast cancer].
Chen S; Huo LQ; Luo S; Wang XX; Xu SJ; Ma Y; Gu HF; Gu J; Lu GM; Zhang LJ
Zhonghua Yi Xue Za Zhi; 2023 Aug; 103(31):2433-2439. PubMed ID: 37599218
[No Abstract] [Full Text] [Related]
16. Prediction of ultrasound guided fine needle aspiration cytology results by FDG PET-CT for lymph node metastases in head and neck squamous cell carcinoma patients.
Peltenburg B; de Keizer B; Dankbaar JW; de Boer M; Willems SM; Philippens MEP; Terhaard CHJ; de Bree R
Acta Oncol; 2018 Dec; 57(12):1687-1692. PubMed ID: 30489180
[TBL] [Abstract][Full Text] [Related]
17. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
Choi WH; Yoo IR; O JH; Kim SH; Chung SK
Br J Radiol; 2011 Jul; 84(1003):593-9. PubMed ID: 21081574
[TBL] [Abstract][Full Text] [Related]
18. Sequential
Pietrzak A; Kazmierska J; Cholewinski W
Hell J Nucl Med; 2017; 20 Suppl():80-92. PubMed ID: 29324917
[TBL] [Abstract][Full Text] [Related]
19. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer.
Bae SU; Won KS; Song BI; Jeong WK; Baek SK; Kim HW
Cancer Imaging; 2018 Sep; 18(1):32. PubMed ID: 30217167
[TBL] [Abstract][Full Text] [Related]
20. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
